Gene therapy has been proposed as a means to combat cancer. However, systemic toxicity observed in preclinical trials suggested the importance of selectively targeted delivery and inducible gene expression in tumor tissues. Discovery of radiation-inducible promoter sequences provides one way to minimize inadvertent toxicity from gene therapy in normal tissues. Radiation is administered to selectively induce cytotoxic gene expression in the targeted tumor tissues. With promising results from phase II clinical trials using TNF-expressing adenovirus, it is possible to have radiation-guided gene therapy regimes once the tumortargeted delivery has been achieved. Tumor endothelium is an attractive biological target for gene therapy, because it has the advantage of stability, accessibility, and bioavailability for therapeutic agents. Technological development of DNA microarray, proteomic profiling, and phage-displayed libraries accelerates the identification of tumor-specific endothelial biomarkers and discovery of its relevant affinity reagents for targeted delivery. The application of radiation-guided gene delivery, its amplification, as well as expression of gene therapy presents great opportunities to be employed as an alternative cancer treatment.
Introduction
Since the attempt of human gene transfer in tumor-infiltrating lymphocytes (TIL) in 1989 (1), gene therapy has been considered as an alternative for the treatment of cancer. Although it is well accepted that the success of gene therapy is closely related to our imperfect understanding of human cancer biology, systemic toxicities generated by most of the current gene delivery systems is still a major obstacle in the development of gene therapy (2, 3). Spatially and temporally controlled expression of cytotoxic gene in tumor is critical to prove the concept and evaluate potentials of cytotoxic genes. Discovery of radiation-inducible gene expression (4) and its applications in gene therapies of cancer (5), clearly suggest that the cellular responses to radiation can be explored to selectively deliver therapeutic agents to tumors, and spatially and temporally control expression of cytotoxic therapeutic gene in tumors. With well-documented biological responses to low-dose fractionated radiation of tumor tissues (6, 7), the accumulating data suggest that we have a great opportunity to translate this promising concept into clinical reality by combining gene therapy with radiation. Low-dose irradiation of tumor tissue can be harnessed to improve delivery of therapeutic agents to tumor tissue and subsequently induce gene expression for targeted gene delivery. Radiation following therapeutic gene delivery could induce specific expression of the delivered cytotoxic genes in tumors. This approach could be advantageous in improving tumor control by combining several cytotoxic interventions, and reducing systemic toxicity by targeted gene delivery, as well as spatially and temporally controlled expression in tumor. 
Discovery of Radiation-Inducible Promoter and Its Application in Tumor Gene Therapy
Irradiation (IR) was reported to induce the expression of the Egr1 gene (4, 8) . Subsequently, one piece of DNA sequence, called CArG box [CC(A+T-rich)6GG] elements in the 5ʹ promoter of radio-responsive genes, was found to be necessary and sufficient for radiation-induced gene expression (8). This discovery initiated the development of radiationcontrolled expression of cytotoxic genes in tumor tissues, to selectively kill cancer cells while avoiding systemic toxicity (9). The first experiment to prove this concept was conducted by direct injection of the radiation-inducible TNF-αexpressing construct into the tumor xenografts (10). Radiation-inducible TNF-α expression and tumor regression were achieved with irradiation after the injection. Moreover, no local or systemic toxicity was observed at therapeutically effective doses. Most importantly, it was also found that this approach was effective in overcoming radio-resistance in tumors (11). Histopathological analysis of the treated tumors revealed that the tumor shrinkage was due to the direct killing of tumor cells through apoptosis and necrosis by secondary to tumor-associated blood vessel thrombosis and destruction. Derivates of this approach were introduced and evaluated in preclinical studies, using genetically modified adenovirus as the delivery vehicle (5, 12). One of the constructs, TNFerade™, was studied in clinical trials, in which it was intratumorally injected, followed by fractionated irradiation. Objective tumor responses, as revealed by pathological analysis and tumor regressions, were observed in clinical trials and the combination of radiation and TN-Ferade™ proved to be well tolerated in patients and subsequently, more effective than radiation alone (5, 13).
Although the preclinical and clinical trials of the radiationguided gene therapy of cancer afforded conclusive and promising results, the local tumor control benefits were achieved by repeated intratumoral injection of the recombinant adenovirus containing the TNF-encoding gene regulated by the radiation-inducible promoter. As revealed by histological examinations, the biological effects of this approach on tumor growth were due to the blocking of tumor-associated blood vessels, thereby resulting in starvation of the tumor cells. Systemic delivery of the agents via the circulation seems to be a plausible approach to improved accessibility of the therapeutic agents to blood vessels, especially for those tumors that are not easily accessible for repeated intratumoral injections (e.g., brain and lung cancer).
Tumor-Targeted Gene Delivery
Currently, most delivery vehicles for gene therapy are based on engineered virus. Although some viruses, like adenovirus used for the above construct, are based on a range of some naturally restricted host cells, most of them are still not suitable for systemic delivery of genes to tumor because of non-specific binding to other normal tissues (2, 3). Studies revealed mechanisms of virus-host interactions, virus entry, and replication taking place inside the cells. For example, transduction by adenovirus is dependent on the abundance of the cell surface receptor known as coxsackievirus and adenovirus receptor (CAR), so cells that lack CAR are usually poorly infected by adenovirus (14) . Understanding of these virus-host interactions enables us to genetically decorate the virus surface with tumor-specific ligands, to replace the natural binding sites for cellular receptors. This modification has been reportedly successful in limiting tissue tropisms in adenovirus (15) and HSV (16) and other viral systems. Biomarkers in tumors allow for this tumor-targeted gene delivery. Bioavailability, consistency among tumors, critical importance for tumor development along with the growth, and dramatic difference from normal vessels make tumor-associated endothelium as an attractive target for tumor-targeted gene delivery. So far, diverse approaches have been employed to survey gene expression patterns at various levels, such as DNA microarray for mRNA alterations (17) (18) (19) , proteomic profiling and protein/antibody array for protein and post-translational modification (20-22), and phage display for ligand binding properties (23-25). Among these approaches, phage displayed peptides and antibody fragments stand out to be extremely important, because the isolated tumor-binding ligands could be directly translated to tumor-targeted gene delivery.
Phage display technology, conceptively developed by George Smith (26, 27) , in which coding regions for peptide or protein segments are inserted in a bacteriophage genome and the peptide or protein segments are expressed on the phage surface to be accessible for molecular interactions. In this approach, a library with diverse peptides was firstly generated by inserting randomized nucleotide sequences into the phage genome, and the diversified phage particles were then "biopanned" over the desired target in an affinity-based manner (28). The physical linkage between the displayed entity (phenotype) and its genetic code (genotype) permits a method for fast decoding of the primary sequence information of the isolated peptides or proteins. Since its first implantation for biological research, phage display technology has evolved dramatically, from filamentous M13 phage as a display format, to diverse platforms using M13, T7, and lambda phages, as well as from shorter peptides as displayed entities, to larger protein and antibody fragments (29-32). For the "biopanning" process, besides using purified molecules as affinity targets, more sophisticated targets, such as molecular complex, cells and organs have been successfully used for in vitro and in vivo "biopanning" (24, (33) (34) (35) . Because the whole-cell or tissue biopanning bypasses the time-and costconsuming purification of the target protein, this method is attractive for developing affinity reagents against targets that are unknown or hard to purify, such as membrane proteins in tumor blood vessels. In vivo selection simultaneously provides positive and subtractive screens because organs and tissues such as tumors are spatially separated. Since great diversity (billions of peptides in one library) has been achieved with chemical and biological approaches, it is possible that any molecule in nature could match up with one or more specific peptide sequences with reasonable affinity and specificity. The enrichment generated by affinity "purification" and biological replication of the "purified" phages makes it assumable to have specific peptides binding with any molecular targets, including the rare ones. Once the affinity reagents are in hand, the corresponding interacting molecules or "receptors" in the biological samples can be further isolated and identified by using biochemical methods. Table I , some tumor endothelium-specific and even stage-specific peptides have been isolated and their specificity was confirmed by tissue and cell staining, as well as the receptor identification for some ligands. Ligands and antibodies that bind to this radiation-inducible receptor were effective in targeting nano-particles to tumor blood vessels and improving the efficacy of therapy in preclinical models. Selective tumor-targeted drug deliveries were achieved by using these peptide ligands (33), in line with this, we found that one of these peptides that binds to the radiation-inducible receptor α2bβ3 can be used for drug delivery (57). We explored this approach in the discovery of tumor endothelium-specific and radiation-inducible bio-markers in tumors (unpublished by Han, Z. and Hallahan, D. E.). By screening phage displayed peptide libraries, we isolated peptides with specificity for tumor-related endothelium and radiated-treated tumors. Since the peptides specific for tumor can be grafted onto surfaces of viral or synthetic delivery vehicles (25, (58) (59) (60) , one peptide that adheres to radiation-treated tumor endothelium for extensively prolonged time is most appropriate for radiation-guided, tumor endothelium-targeted gene, and drug delivery.
As listed in
Using the same concept, one report (61) showed that it is also possible to display the random peptides on viral surface, and screen the recombinant viruses for targeting vectors that can be directly used for gene delivery. Although technologies, such as the bioinformatics approach (23), affinity-based separation (46), and expression cloning (62), have been developed to identify putative receptors for the tumor-specific ligands, relative low affinity and specificity of the short peptides for putative receptors complicate the identification of the corresponding putative receptor. Larger structural entities, such as engineered antibody fragments and other scaffold proteins (63-65), might be alternative sources of combinatorially diversified sequences for profiling the differences among tissues. More stable structures in these larger entities would ensure higher specificity; larger interaction surfaces provided by these scaffolds would also contribute more energy and thus higher affinity to the molecular interactions. These properties would make it easier to identify putative receptors and apply the specific ligands for ligand-guided drug delivery. In addition to the direct isolation of tumor-specific ligands for tumor-targeted gene delivery, the targeting peptides and antibodies can also be more rationally designed and screened on the identified tumor-specific targets. DNA microarray, proteomics, and antibody array approaches have explored a number of biomarkers for tumors and other pathological tissues in this post-genomics era. Large-scale sample profiling has been realized with the development of high throughput technologies; bioinformatics makes it possible to track and analyze tones of experimental data. Taken together, each of these approaches contribute to the accumulation of biomarkers discovered in tumors. Affinity reagents (peptides, antibodies, and engineered scaffold proteins) can, therefore, be isolated and used for tumor-specific therapeutic gene delivery.
Since radiation induces inflammation in tissues, it is reasonable to speculate that inflammation-responsible molecules could be elevated by radiation in tumor, and, thus, could be used as molecular targets for therapeutics deliveries. In the past few years, several adhesion molecules, such as P-selectin (CD62P), E-selectin, ICAM-1, and integrins, which are involved in the inflammatory response, have also been identified to be inducible with radiation in the tumor blood vessels. These inflammation-related molecules can be regulated through transcription or translocated from intracellular storage reservoirs. These molecules are involved in the initiation of leukocyte adhesion and extravasations at the vascular endothelium, platelet aggregation, and inflammatory cell activation (66-70). These radiation-induced receptors have been used to target drug and gene therapies to tumors after irradiation (71-73). Internalization of delivered genes to the targeted cells is critical for successful gene expression. In terms of this internalization requirement, P-selectin could be further explored as a target for radiation-guided gene delivery. P-selectin (also known as CD62P, LECAM-3, GMP-140, or PADGEM) is a highly glycosylated protein of 140 kD, which is constitutively expressed and stored in secretory granules in endothelial cells (Weibel-Palade bodies) and platelets (α-granules). Although mRNA level of P-selectin was reportedly elevated by inflammatory stimuli, such as radiation, the most immediate response of P-selectin to inflammatory stimuli is relocating from storage reservoirs to the surface of endothelial cells via exocytosis. The storage granules fuse with the plasma membrane and expose P-selectin on the surface (74). P-selectin on the endothelium works as a primary adhesion site for circulating leukocytes on the activated endothelial cells (66). After the initial binding to its ligands, P-selectin, along with its binding ligand (such as antibody) is rapidly internalized via endocytosis and recycled to the storage reservoirs (75). This recycling process would be attractive for gene and drug deliveries, which heavily rely on internalization for exercising functions, especially for non-virally vectored deliveries. This re-localization of P-selectin is time dependent, beginning at one hour post-irradiation and increasing up to 24 hours (74).
Encouraged with these discoveries, we used phage-displayed combinatorial library to screen antibody fragments, which can specifically bind with P-selectin. Staining of HUVEC ( Figure 1A) treated with radiation and other inflammation stimuli indicated that the antibody binding to the exposed P-selectin is treatment specific. Biodistribution of the antibody in tumor-bearing animals was studied with near infrared imaging ( Figure 1B) , in which the tumor-bearing mice were irradiated at one tumor and another tumor was left as an untreated control. The animals were then intravenously injected with dye-labeled antibody. Near infrared (NIR) total body images were taken at different time points to determine Tumor-bearing mice were irradiated at one tumor (in the left hind limb), while the other tumor (in the right hind limb) was left as an untreated control; Cy7-labeled antibody was intravenously injected via tail vein at 4 hours after radiation. NIR total body images were taken at different time points to determine relative distribution of the antibody in the animals. The representative pictures were taken at 4 hours after the injection.
relative distribution of the antibody in the animals. The results suggested that the antibody selectively accumulated in the irradiated tumor regions (unpublished by Hallahan, D. E.) . This discovery, as well as the internalization of P-selectin and its associated binding partners documented by other groups, encourages us to test the possibility of delivering genes to irradiated tumor by targeting P-selectin.
Radiation was reported to induce permeability of vasculatures, and probably by reorganizing the membrane-associated proteins (76). We hypothesized that radiation induces signal transduction to reorganize cellular membrane for physiological response to the stimulation, and these conformational changes represent another source of radiation-induced biomarkers for gene delivery. As suggested by other documented successes (77-79), we used membrane-impermeable biotinylation reagents to selectively tag any solventaccessible epitopes on cell membrane, sheared the tagged peptide segments off the insoluble membrane by using protease, and concentrated the tagged peptide on neutravidinbased affinity column for mass spectrometric identification.
To test the implanted methods in our laboratory, first we compared Human Umbilical Vein Endothelial Cells (HUVEC) and cancer cell-cocultured HUVEC. Cancer cells secrete growth factors and modulate physiologically and morphologically the adjacent endothelial cells (19), so a comparison of MS profiles of samples from these two conditioned cells can be used to evaluate this protocol. LC-MS analysis shows that several proteins were induced on HMVEC by coculturing with H460 tumor cell that include some identified proteins essential for adherence of tumor cells to endothelial cells tumor growth and formation of neovasculature, such as perlecan (80), CYR61 (81), and the hedgehog-interacting protein (82). This approach indicated several advantages over other traditional sample preparation and fractionation methods. Biotinylation and affinity purification make this approach more sensitive than most of the current methods, by enriching even the rare peptides. Analysis of the digested membrane-associated proteins makes it possible to survey the hydrophobic and insoluble membrane proteins, and selection of hydrophilic, membrane-impermeable biotinylation reagent allows only the proteins associated with outer cell membrane to be biotinylated and analyzed, thus reducing the analytical contents.
We also surveyed differences in irradiated and untreated HUVEC outer membranes, which had been co-cultured with tumor cells. The co-culture system has been documented as an in vitro model of tumor-associated endothelial cells. The results indicated that irradiation induced conformational alterations in several proteins, as illustrated in Figure 2 using perlecan as an example. Multiple fragments in perlecan were detected in both of the samples prepared from radiation-treated and untreated HUVEC cells, as listed in the Figure 1 . The left column indicates the untreated cells and the right column indicates the irradiated cells. 2Gy irradiation induced exposure of some epitopes in perlecan for solvent-access and biotinylation (bold in the right), and also concealed some epitopes (as shown as grey text). This conformational change in membrane-associated proteins might result from radiation-induced ligand binding or disassociation, or membrane rearrangement. Although the mechanisms and biological relevance for these conformational changes need to be studied further, this experiment also suggested some potentials of these conformational changes as biomarkers for treatment indication and targets for sequential drug delivery.
Signal Amplification In Situ: Inducible Gene Replication
In addition to targeted gene delivery and site-specific induction of gene expression, selective gene replication is another way to improve efficacy of tumor-targeted therapeutic gene (85, 86) . Strategies employed for tumor-selective gene replication can be grouped into three general approaches. The first approach is to delete gene functions that are critical for efficient viral replication in normal cells but dispensable in tumor cells, exemplified by the creation of the replication-selective adenovirus mutant ONYX-015. The second approach is to limit the expression of a critical viral gene to tumor tissues through the use of tumor-and/or tissue-specific promoters, represented by the adenovirus mutant CV706 (87). The third general approach is to alter viral tropism through modification of surface proteins (15), by using tumor-specific ligands discussed as above to direct selective infection of tumors by using the engineered virus. Other than the adenovirus E1B gene, other genes critical for virus replication in normal cells, such as thymidine kinase (TK) (88), and vaccinia growth factor (VGF) (89), have also been explored for tumor-selective virus replication. Recently, radiation-potentiated virus replication was discovered in HSV (90, 91). It was found that radiation not only potentiated virus replication and tumor cell killing (92), but the regulated gene replication also overcame radiation resistance in the infected tumor cells in vitro and in vivo.
Conclusion and Perspectives
Given the progress in tumor-specific targeting ligand discovery, as well as understanding of radiation-regulated gene replication and transcription, gene therapy of cancers has presented great for translation to clinical trials. Since no single approach achieves complete efficacy in tumor control, it has been proposed that the combination of two or more interventions would result with improved tumor control. Radiation has been used in most cancer patients. Technological and scientific advances ensure precise delivery of radiation to tumor sites. Low-dose radiation has been reported to enhance drug delivery to solid tumors (6). We can expect therapeutic regimes in which fractionated radiation and tumor-targeted therapeutic gene delivery would be combined to improve tumor control. The fractionated low-dose radiation can be used to enhance drug accessibility of solid tumors and induce specific biomarker expression for tumor-targeted gene delivery. One recent publication partially supports this concept by showing the radiation-induced Dynamin 2 expression and increased adenovirus uptake and gene expression in cells in colon cancer xenografts (93). After the gene delivery vehicles clear from the circulation and normal tissues, subsequent irradiation can be used to induce selective gene replication (for amplified anti-tumor effect) and therapeutic gene expression to achieve tumor-limited cytotoxicity.
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